Capital Group Crosses 5.00% Threshold in AstraZeneca (AZN) — TR-1 Notice

AstraZeneca received a TR-1 notification showing The Capital Group Companies, Inc. and its investment management affiliates crossed the 5% voting threshold in AstraZeneca ordinary shares on 11-Aug-2025.

Rhea-AI Filing Summary

AstraZeneca received a TR-1 notification showing The Capital Group Companies, Inc. and its investment management affiliates crossed the 5% voting threshold in AstraZeneca ordinary shares on 11-Aug-2025. The notification reports a resulting total holding of 5.000629% of voting rights, represented by 77,294,699 underlying voting rights and 14,394,421 depository receipts (ISIN US0463531089) accounting for 0.928264% of voting rights. The filing discloses the full chain of controlled undertakings through which the holdings are held and explains these shares are owned by client accounts under discretionary management by Capital Group entities rather than for Capital Group's own account.

Positive

• Regulatory compliance: The TR-1 notification provides timely disclosure of a major holding above 5%, meeting transparency requirements
• Clarity of ownership: Filing details the chain of controlled undertakings and states holdings are held in discretionary client accounts, clarifying economic ownership
• Specific metrics provided: Reports precise figures including 5.000629% total voting rights, 77,294,699 voting rights, and 14,394,421 depository receipts (ISIN US0463531089)

Negative

• None.

Insights

Financial Analyst

TL;DR: Capital Group crossed the 5% voting threshold in AZN, reporting 5.000629% total voting rights as of 11-Aug-2025.

The notification is a standard major-holding disclosure showing an institutional investor now holds just above the 5% threshold in AstraZeneca. The breakouts list 77,294,699 voting rights and 14,394,421 depository receipts (ISIN US0463531089) contributing 0.928264% of votes. The filing clarifies these positions are held on behalf of discretionary client accounts across Capital Group affiliates rather than on the parent company's own balance sheet. For investors, the development signals that a large, diversified investment manager has a notable stake, but the holding size is marginal relative to total market capitalization and does not by itself convey strategy or intent.

Corporate Governance Expert

TL;DR: Disclosure complies with TR-1 requirements; the filing identifies the controlling chain and clarifies proxy/ownership arrangements.

The report meets regulatory transparency expectations by naming The Capital Group Companies and affiliated management entities, providing the date the threshold was crossed (11-Aug-2025), and specifying the ownership structure and that shares are held for client accounts. The filing does not state any proxy voting arrangements beyond identifying the reporting group, nor does it indicate changes to board or governance plans. As presented, it is a routine regulatory disclosure of a passive institutional stake.

FAQ

What stake in AstraZeneca (AZN) did The Capital Group report?

The Capital Group reported a resulting total holding of 5.000629% of voting rights in AstraZeneca as of 11-Aug-2025.

When did the 5% voting threshold get crossed for AZN?

The threshold was crossed or reached on 11-Aug-2025 according to the TR-1 notification.

How many voting rights and depository receipts were reported?

The filing shows 77,294,699 voting rights and 14,394,421 depository receipts (ISIN US0463531089), the latter representing 0.928264% of voting rights.

Are the shares owned by Capital Group for its own account?

No; the notification states the shares are owned by accounts under the discretionary investment management of Capital Group investment management companies, not for the parent company's own account.

What entities within Capital Group are identified in the filing?

The filing names The Capital Group Companies, Inc., Capital Research and Management Company, Capital Bank & Trust Company, and several Capital International affiliates as part of the ownership chain.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 08/12/2025 - 10:45 AM Learn about SEC filing dates

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of

the Securities Exchange Act of 1934

For the month of August 2025 

Commission File Number: 001-11960

AstraZeneca PLC

1 Francis Crick Avenue

Cambridge Biomedical Campus

Cambridge CB2 0AA

United Kingdom

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F X Form 40-F __

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ______

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes __ No X

If “Yes” is marked, indicate below the file number assigned to the Registrant in connection with Rule 12g3-2(b): 82-_____________

AstraZeneca PLC

INDEX TO EXHIBITS

1.

Holding(s) in Company

TR-1: Standard form for notification of major holdings

1. Issuer Details

ISIN

GB0009895292

Issuer Name

ASTRAZENECA PLC

UK or Non-UK Issuer

UK

2. Reason for Notification

An acquisition or disposal of voting rights

3. Details of person subject to the notification obligation

Name

The Capital Group Companies, Inc.

City of registered office (if applicable)

Los Angeles

Country of registered office (if applicable)

USA

4. Details of the shareholder

Full name of shareholder(s) if different from the person(s) subject to the notification obligation, above

City of registered office (if applicable)

Country of registered office (if applicable)

5. Date on which the threshold was crossed or reached

08-Aug-2025

6. Date on which Issuer notified

11-Aug-2025

7. Total positions of person(s) subject to the notification obligation

	% of voting rights attached to shares (total of 8.A)	% of voting rights through financial instruments (total of 8.B 1 + 8.B 2)	Total of both in % (8.A + 8.B)	Total number of voting rights held in issuer
Resulting situation on the date on which threshold was crossed or reached	4.984560	0.000000	4.984560	77294699
Position of previous notification (if applicable)	5.000629	0.000000	5.000629

8. Notified details of the resulting situation on the date on which the threshold was crossed or reached

8A. Voting rights attached to shares

Class/Type of shares ISIN code(if possible)	Number of direct voting rights (DTR5.1)	Number of indirect voting rights (DTR5.2.1)	% of direct voting rights (DTR5.1)	% of indirect voting rights (DTR5.2.1)
GB0009895292 Common Stock		62900278		4.056296
US0463531089 Depository Receipt		14394421		0.928264
Sub Total 8.A	77294699		4.984560%

8B1. Financial Instruments according to (DTR5.3.1R.(1) (a))

Type of financial instrument	Expiration date	Exercise/conversion period	Number of voting rights that may be acquired if the instrument is exercised/converted	% of voting rights
Sub Total 8.B1

8B2. Financial Instruments with similar economic effect according to (DTR5.3.1R.(1) (b))

Type of financial instrument	Expiration date	Exercise/conversion period	Physical or cash settlement	Number of voting rights	% of voting rights
Sub Total 8.B2

9. Information in relation to the person subject to the notification obligation

2. Full chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held starting with the ultimate controlling natural person or legal entities (please add additional rows as necessary)

Ultimate controlling person	Name of controlled undertaking	% of voting rights if it equals or is higher than the notifiable threshold	% of voting rights through financial instruments if it equals or is higher than the notifiable threshold	Total of both if it equals or is higher than the notifiable threshold
The Capital Group Companies, Inc.	Capital Research and Management Company
The Capital Group Companies, Inc.	Capital International, Inc.
The Capital Group Companies, Inc.	Capital Group Private Client Services, Inc.
The Capital Group Companies, Inc.	Capital International Sarl
The Capital Group Companies, Inc.	Capital International Limited

10. In case of proxy voting

Name of the proxy holder

The number and % of voting rights held

The date until which the voting rights will be held

11. Additional Information

The Capital Group Companies, Inc. ("CGC") is the parent company of Capital Research and Management Company ("CRMC") and Capital Bank & Trust Company ("CB&T"). CRMC is a U.S.-based investment management company that serves as investment manager to the American Funds family of mutual funds, other pooled investment vehicles, as well as individual and institutional clients. CRMC and its investment manager affiliates manage equity assets for various investment companies through three divisions, Capital Research Global Investors, Capital International Investors and Capital World Investors. CRMC is the parent company of Capital Group International, Inc. ("CGII"), which in turn is the parent company of six investment management companies ("CGII management companies"): Capital International, Inc., Capital International Limited, Capital International Sàrl, Capital International K.K., Capital Group Private Client Services Inc, and Capital Group Investment Management Private Limited. CGII management companies primarily serve as investment managers to institutional and high net worth clients. CB&T is a U.S.-based registered investment adviser and an affiliated federally chartered bank.Neither CGC nor any of its affiliates own shares of the Issuer for its own account. Rather, the shares reported on this Notification are owned by accounts under the discretionary investment management of one or more of the investment management companies described above.

12. Date of Completion

11-Aug-2025

13. Place Of Completion

Los Angeles

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

AstraZeneca PLC

Date: 12 August 2025

By: /s/ Matthew Bowden

Name: Matthew Bowden

Title: Company Secretary